Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Established in 2008 and based in York, United Kingdom, Abingdon Health Plc is a global entity dedicated to the creation, production, and worldwide distribution of diagnostic instruments. Their product line features the AbC-19 Rapid Test, a fast-acting diagnostic for COVID-19 IgG antibodies, alongside various nucleic acid lateral flow immunoassays. They also offer Seralite, a swift lateral flow test for accurately measuring kappa and lambda immunoglobulin free light chains in blood serum. Additionally, their AppDx technology converts any smartphone into an autonomous and adaptable lateral-flow reader. Beyond these offerings, the company provides expert services in lateral flow development and manufacturing, as well as advisory support to firms in the health tech industry. Abingdon Health Plc also engages in a collaborative and co-marketing partnership with Abcam plc.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Target Price
The average target price of ABDX.L is 19.0 and suggests 72.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in